IKK/NF-B and STAT3 pathways: Central signalling hubs in inflammation-mediated tumour promotion and metastasis

EMBO Reports

Volumn 10, Issue 12, 2009, Pages 1314-1319

  Bollrath, Julia ^a   Greten, Florian R ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Carcinogenesis; Inflammation; Myeloid cells; Signal transduction

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CHEMOKINE; CYTOKINE; CYTOTOXIC AGENT; I KAPPA B KINASE; I KAPPA B KINASE BETA INHIBITOR; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IS 3 295; PEPTIDE DERIVATIVE; PLATINUM COMPLEX; PROTEIN INHIBITOR; S 31 M 2001; STA 21; STAT3 PROTEIN; STAT3 PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

B CELL LYMPHOMA; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CATALYSIS; CELL COMMUNICATION; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CHOLESTATIC HEPATITIS; COLORECTAL CANCER; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; ENTERITIS; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; INFLAMMATION; LARGE CELL LYMPHOMA; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CIRRHOSIS; LIVER METASTASIS; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULAR DOCKING; MULTIPLE MYELOMA; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME; TUMOR; TUMOR CELL; ANIMAL; BIOLOGICAL MODEL; CELL TRANSFORMATION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; I-KAPPA B KINASE; INFLAMMATION; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; NF-KAPPA B; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 73849090217     PISSN: 1469221X     EISSN: 14693178     Source Type: Journal    
DOI: 10.1038/embor.2009.243     Document Type: Review

References (60)

1. Aggarwal BB, Vijayalekshmi RV, Sung B (2009) Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 15: 425-430
2. Balkwill F, Mantovani A (2001) inflammation and cancer: back to Virchow? Lancet 357: 539-545
3. Baud V, Karin M (2009) Is NF-κB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8: 33-40
4. Becker C et al. (2004) TgF-β suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21: 491-501
5. Bollrath J et al. (2009) GP130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15: 91-102
6. Condeelis J, Pollard JW (2006) Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124: 263-266
7. De Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6: 24-37
8. + t cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16: 91-102
9. Eaden JA, Abrams KR, Mayberry JF (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48: 526-535
10. Eckmann L et al. (2008) Opposing functions of i KK£ during acute and chronic intestinal inflammation. Proc Natl Acad Sci USA 105: 15058-15063
11. Ernst M et al. (2008) Stat3 and Stat1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest 118: 1727-1738
12. Galon J et al. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964
13. Garber K (2009) First results for agents targeting cancer-related inflammation. J Natl Cancer Inst 101: 1110-1112
14. Greten FR et al. (2004) IKK£ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118: 285-296
15. Greten FR et al. (2007) NF-KB is a negative regulator of IL-113 secretion as revealed by genetic and pharmacological inhibition of IKK£. Cell 130: 918-931
16. Grivennikov S et al. (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15: 103-113
17. Groner B, Lucks P, Borghouts C (2008) The function of Stat3 in tumor cells and their microenvironment. Semin Cell Dev Biol 19: 341-350
18. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70
19. He B et al. (2003) SOcS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA 100: 14133-14138
20. Huang S (2007) Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin Cancer Res 13: 1362-1366
21. Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239-252
22. Karin M, Greten FR (2005) NF-KB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5: 749-759
23. Khasawneh J et al. (2009) Inflammation and mitochondrial fatty acid FS-oxidation link obesity to early tumor promotion. Proc Natl Acad Sci USA 106: 3354-3359
24. Kim S et al. (2009) Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457: 102-106
25. Konstantinopoulos PA et al. (2007) EgF-r is expressed and ap-1 and NF-KB are activated in stromal myofibroblasts surrounding colon adenocarcinoma paralleling expression of COX2 and VEgF. Cell Oncol 29: 477-482
26. Kortylewski M et al. (2009) Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 15: 114-123
27. Leibbrandt A, Penninger JM (2008) RaNK/raNKL: regulators of immune responses and bone physiology. Ann NY Acad Sci 1143: 123-150
28. Lin WW, Karin M (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117: 1175-1183
29. Luedde T et al. (2007) Deletion of NEMO/IKK-y in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11: 119-132
30. Luo JL et al. (2007) Nuclear cytokine-activated IKKa controls prostate cancer metastasis by repressing Maspin. Nature 446: 690-694
31. Maeda S et al. (2005) IKKfJ couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121: 977-990
32. Mantovani A (2009) Cancer: inflaming metastasis. Nature 457: 36-37
33. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454: 436-444
34. Mueller L et al. (2007) Stromal fibroblasts in colorectal liver metastases originate from resident fibroblasts and generate an inflammatory microenvironment. Am J Pathol 171: 1608-1618
35. Murdoch C, Muthana M, Coffelt SB, Lewis CE (2008) The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8: 618-631
36. Naugler WE et al. (2007) Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317: 121-124
37. Naugler WE, Karin M (2008) NF-κB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 18: 19-26
38. Pikarsky E et al. (2004) NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 431: 461-466
39. Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265-273
40. Popivanova BK et al. (2008) Blocking tNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 118: 560-570
41. Rebouissou S et al. (2009) Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457: 200-204
42. Rigby RJ et al. (2007) Suppressor of cytokine signaling 3 (SOcS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon. Oncogene 26: 4833-4841
43. Sakurai T et al. (2008) Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 14: 156-165
44. Sherman M (2005) Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 25: 143-154
45. Siddiquee K et al. (2007) Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 104: 7391-7396
46. Smyth MJ, Dunn GP, Schreiber RD (2006) Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90: 1-50
47. Song H, Wang R, Wang S, Lin J (2005) A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA 102: 4700-4705
48. Spaeth EL et al. (2009) Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 4: e4992
49. Sun SC (2008) Deubiquitylation and regulation of the immune response. Nat Rev Immunol 8: 501-511
50. Tebbutt NC et al. (2002) Reciprocal regulation of gastrointestinal homeostasis by SHp2 and Stat-mediated trefoil gene activation in gp130 mutant mice. Nat Med 8: 1089-1097
51. Turkson J et al. (2005) A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem 280: 32979-32988
52. Vakkila J, Lotze MT (2004) Inflammation and necrosis promote tumour growth. Nat Rev Immunol 4: 641-648
53. Vallabhapurapu S, Karin M (2009) Regulation and function of NF-κB transcription factors in the immune system. Annu Rev Immunol 27: 693-733
54. Verma NK et al. (2009) Stat3-stathmin interactions control microtubule dynamics in migrating t-cells. J Biol Chem 284: 12349-12362
55. Wang L et al. (2009) IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206: 1457-1464
56. Wu S et al. (2009) A human colonic commensal promotes colon tumorigenesis via activation of t helper type 17 t cell responses. Nat Med 15: 1016-1022
57. Yu H, Jove R (2004) The Stats of cancer\-new molecular targets come of age. Nat Rev Cancer 4: 97-105
58. Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: role of Stat3 in the tumour microenvironment. Nat Rev Immunol 7: 41-51
59. Zhang J et al. (2006) Impaired regulation of NF-κB and increased susceptibility to colitis-associated tumorigenesis in cyLD-deficient mice. J Clin Invest 116: 3042-3949
60. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8: 59-73